Nivolumab/Ipilimumab
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transitional Cell Carcinoma
Conditions
Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer
Trial Timeline
Jul 6, 2017 → Feb 18, 2023
NCT ID
NCT03219775About Nivolumab/Ipilimumab
Nivolumab/Ipilimumab is a phase 2 stage product being developed by Bristol Myers Squibb for Transitional Cell Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03219775. Target conditions include Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03219775 | Phase 2 | UNKNOWN |
| NCT02917772 | Phase 2 | Completed |
Competing Products
20 competing products in Transitional Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab vedotin | Astellas Pharma | Phase 2 | 52 |
| enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine | Astellas Pharma | Phase 1/2 | 41 |
| Pemetrexed + Gemcitabine + Platinol | Eli Lilly | Phase 1/2 | 41 |
| Vepugratinib + EV + Pembrolizumab | Eli Lilly | Phase 3 | 77 |
| durvalumab and tremelimumab | AstraZeneca | Phase 2 | 52 |
| Docetaxel + vandetanib + Placebo | AstraZeneca | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Everolimus + Everolimus + Paclitaxel | Novartis | Phase 2 | 52 |
| Buparlisib | Novartis | Phase 2 | 52 |
| BEZ235 | Novartis | Phase 2 | 52 |
| Atezolizumab | Roche | Phase 3 | 77 |
| Gemcitabine + Cisplatin + Sunitinib Malate | Pfizer | Phase 2 | 51 |
| vinflunine and best supportive care | Bristol Myers Squibb | Phase 3 | 76 |
| vinflunine | Bristol Myers Squibb | Phase 2 | 51 |
| Dasatinib | Bristol Myers Squibb | Pre-clinical | 22 |
| Docetaxel + Oxaliplatin | Sanofi | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2/3 | 64 |
| Rogaratinib (BAY1163877) + Chemotherapy | Bayer | Phase 2/3 | 62 |
| CG0070 Adenovirus Vector | CG Oncology | Phase 2/3 | 62 |